Progress on EGFR-TKI in treatment of non-small cell lung cancer with S768I mutation
10.3969/j.issn.1000-8179.2017.22.824
- VernacularTitle:EGFR-TKI治疗S768I突变非小细胞肺癌的研究进展
- Author:
DUAN HUA
1
,
2
;
北京中医药大学
Author Information
1. 中日友好医院中西医结合肿瘤内科(北京市100029)
2. 北京中医药大学
- Keywords:
epidermal growth factor receptor-tyrosine kinase inhibitor;
exon;
S768I mutation;
advances
- From:
Chinese Journal of Clinical Oncology
2017;44(22):1155-1159
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is one of the malignant tumors with high mortality rates. In recent years, considerable progress on the treat-ment of non-small cell lung cancer has been achieved. Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) improves the median progression free survival of patients with sensitive mutations to 27.7 months. However, the therapeutic effect of EGFR-TKI on uncommon mutations remains unknown. S768I mutation is an insensitive mutation in the EGFR20 exon, and its incidence rate rang-es from 1％to 2％. In this review, the effect of different generation EGFR-TKI on single or complex S768I mutation during treatment is discussed.
